Introduction Epidermal growth factor receptor (EGFR) is one of the most common driver
gene mutations in non-small-cell lung cancer (NSCLC). EGFR-tyrosine kinase inhibitors …

Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitors (TKIs) have changed
the paradigm of treatment in non-small cell lung cancer (NSCLC). The molecular biology …

Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are the standard
first-line option for non-small-cell lung cancer (NSCLC) harboring active EGFR mutations …

EGFR tyrosine kinase inhibitors are currently included in the therapeutic armamentarium
against advanced NSCLC. However, many questions on the use of anti-EGFR treatment in …

Introduction: Epidermal growth factor receptor (EGFR) mutations are well-described drivers
of non-small cell lung cancer (NSCLC) and EGFR tyrosine kinase inhibitors (TKIs) have …

First-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs),
including gefitinib and erlotinib, have proven to be highly effective agents for advanced non …

The epidermal growth factor receptor (EGFR) mutation is a potent oncogenic driver that
accounts for carcinogenesis and tumor growth of pulmonary adenocarcinoma. Targeting …

Objective To determine the efficacy of first-generation epidermal growth factor receptor
tyrosine kinase inhibitors (EGFR-TKIs) in molecularly selected patients with advanced non …

Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are the current
recommended option for the first-line treatment of patients with EGFR-mutant non-small cell …

Background EGFR mutation status is closely related to the efficacy of EGFR-TKIs in
advanced non-small cell lung cancer (NSCLC). EGFR-TKIs have become the standard first …